Prothena, Roche target alpha-synuclein in $600M Parkinson’s pact
DUBLIN – Shares in Prothena Corp. plc should get a pre-Christmas boost when Nasdaq opens on Thursday morning to news of a drug development deal in Parkinson’s disease with Roche Holding AG worth up to $600 million in up-front and milestone payments.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST